Trials / Completed
CompletedNCT03436693
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
A Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 308 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 30 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Canagliflozin | Canagliflozin 100mg orally once daily |
| DRUG | Placebo | Placebo orally once daily |
Timeline
- Start date
- 2018-02-15
- Primary completion
- 2021-01-21
- Completion
- 2021-01-21
- First posted
- 2018-02-19
- Last updated
- 2026-01-07
- Results posted
- 2024-07-15
Locations
26 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03436693. Inclusion in this directory is not an endorsement.